GH Bardy - US Patent 7,874,993, 2011 - Google Patents Illllllllllllllllllllllllllllllllllllllllllllllllll US007874993B2 (12) United States Patent Bardy (io) Patent No.: (45) Date of Patent: US 7,874,993 B2 *Jan. 25, 2011 (54) SYSTEM AND METHOD FOR DIAGNOSING AND MONITORING CONGESTIVE HEART FAILURE (75) Inventor: Gust H. ... Related articles - All 4 versions
D Cowart, J Aranda, G Haas… - Journal of the …, 2011 - Am Coll Cardio Found ... Mazhari, Vince Kalish, and Wilson Colucci Doug Cowart, Juan Aranda, Garrie Haas, Joel Neutel, William Smith, Reza CONGESTIVEHEARTFAILURE A NOVEL HNO DONOR, CXL-1020, IN PATIENTS WITH STABLE A PHASE I/IIA FIRST IN MAN SAFETY AND TOLERABILITY ... All 2 versions
KE Joynt, EJ Orav… - Annals of internal medicine, 2011 - Am Coll Physicians ... The Association Between Hospital Volume and Processes, Outcomes, and Costs of Care for CongestiveHeartFailure. ... Abstract. Background: Congestiveheartfailure (CHF) is common and costly, and outcomes remain suboptimal despite pharmacologic and technical advances. ... Cited by 3 - Related articles - All 5 versions
KE Joynt, EJ Orav… - Annals of Internal Medicine, 2011 - Am Coll Physicians TO THE EDITOR: Although some studies suggest that patients aged 75 years or older derive benefit from primary prophylactic implant- able cardioverter-defibrillator (ICD) therapy similar to that of their younger counterparts (1), consideration of age and noncardiac co- morbid ...
[HTML] from jcojournal.orgCJ Richards, Y Je, FAB Schutz… - Journal of Clinical …, 2011 - jcojournal.org Purpose Sunitinib is a multitargeted receptor tyrosine kinase inhibitor approved for treatment of renal cell carcinoma (RCC) and GI stromal tumor. Congestive heart failure (CHF) is an important adverse effect that has been reported with sunitinib, but overall incidence and relative risk ...
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
